Overview

* Tenaya Therapeutics ( TNYA ) Q2 net loss of $23.3 mln narrows

* Co completes enrollment in key gene therapy trials, enabling dose expansion

* Cash reserves expected to support operations into second half of 2026

Outlook

* Tenaya anticipates TN-201 and TN-401 data readouts in Q4 2025

* Company expects cash runway into second half of 2026

Result Drivers

* TRIAL ENROLLMENT - Completion of enrollment in TN-201 and TN-401 trials enables dose expansion, per CEO Faraz Ali

* SAFETY APPROVAL - Positive DSMB safety review allows dose escalation for TN-201 and TN-401 trials

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net Beat -$23.28 -$25.90

Income mln mln (5

Analysts

)

Q2 Beat -$24.08 -$26.30

Operatin mln mln (4

g Income Analysts

)

Q2 Beat -$23.28 -$25.90

Pretax mln mln (5

Profit Analysts

)

Q2 Basic -$0.14

EPS

Q2 $24.08

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Tenaya Therapeutics Inc ( TNYA ) is $5.00, about 86.1% above its August 5 closing price of $0.70

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)